RNFL loss tied to slower reaction times

Article

Glaucomatous structural damage may affect an individual's ability to divide attention when performing daily tasks such as driving, according to research recently published online.

Glaucomatous structural damage may affect an individual's ability to divide attention when performing daily tasks such as driving, according to research recently published online.

Researchers at the Hamilton Glaucoma Center, University of California San Diego, USA, conducted a cross-sectional observational study of 158 subjects from the Diagnostic Innovations in Glaucoma Study: 82 subjects with glaucoma and 76 controls of similar age.

The researchers measured the subjects’ reaction times to peripheral stimuli at low, medium, or high contrast while the subjects performed simulated driving tasks such as negotiating a curve or following another car.

They discovered that the glaucoma subjects' mean reaction times to the low contrast stimulus were 1.19 seconds for car following and 1.05 seconds for curve negotiation. The control subjects’ reaction times were 0.77 seconds and 0.64 seconds, respectively, for the two tasks.

A non-linear relationship was found between reaction times and the retinal nerve fibre layer thickness (RNFL) in the subjects’ better eye. After the researchers adjusted for factors such as age, cognitive ability and standard automated perimetry deviation in the better eye, RNFL thickness still remained significantly associated with reaction times.

"Information from structural tests may improve our ability to determine which patients are likely to have problems performing daily activities, such as driving," the researchers concluded.

To read an abstract of the study visit the American Journal of Ophthalmology.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.